Nitrogen Or Additional Chalcogen Bonded Directly To Ring Carbon Of The Thiadiazole Ring Patents (Class 548/130)
  • Publication number: 20150038538
    Abstract: The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Applicant: ASD THERAPEUTICS PARTNERS LLC
    Inventors: Miguel Medina Padilla, Juan Manuel Domínguez Correa, Javier De Cristobal Blanco, Ana Fuertes Huerta, Jorge Sánchez-Quesada, Javier López Ogalla, Susana Herrero Santos, María Ángeles Pérez De La Cruz Moreno, Olga Martínez Montero, Beatriz Rodríguez Salguero, Francisco Palomo Nicolau
  • Patent number: 8865750
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 21, 2014
    Assignees: The Regents of The University of Michigan, The University of Bath
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor
  • Publication number: 20140275524
    Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One”).
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Lindsey G. Fischer, Andrew L. Ward, Ronald Ross, JR., Natalie C. Giampietro, Carl DeAmicis, Yan Hao, Gary D. Crouse, Thomas C. Sparks, Erich W. Baum, Jeff Petkus
  • Publication number: 20140275047
    Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One”).
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Lindsey G. Fischer, Erich W. Baum, Gary D. Crouse, Jeff Petkus, Andrew L. Ward, Thomas C. Sparks
  • Patent number: 8552175
    Abstract: The use of N-formamidino-5-amino-3H-1,2,4-dithiazole-3-thiones, 5-phenyl-3H-1,2,4-dithiazole-3-thiones, and derivatives thereof as novel, efficient sulfur-transfer reagents is disclosed. Sulfur transfer from these reagents to compounds containing a P(III) atom (e.g., triphenylphosphine, 5?-O-DMT-thymidine 2-cyanoethyl-(N,N-diisopropyl)phosphoramidite, and 5?-O-DMT-3?-O-levulinyl dithymidilyl 2-cyanoethyl phosphite), was studied in solution by 31P NMR and HPLC. The sulfur transfer from title compounds was also studied in the solid-phase synthesis of oligonucleotide phosphorothioates by phosphoramidite methods. In this application, the efficiency of the sulfur transfer reaction for 2?-deoxyoligonucleotides was better than 99.5%. The novel sulfurizing agents are synthesized, at low cost, using simple chemical methods.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: October 8, 2013
    Assignee: A.M. Chemicals, Inc.
    Inventor: Andrei P. Guzaev
  • Patent number: 8344004
    Abstract: The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 1, 2013
    Assignee: Sanofi
    Inventors: Karl Schoenafinger, Stefanie Keil, Matthias Urmann, Hans Matter, Maike Glien, Wolfgang Wendler, Ulrike Wendler, legal representative
  • Publication number: 20120277273
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor
  • Publication number: 20120183537
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—, —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Application
    Filed: July 8, 2010
    Publication date: July 19, 2012
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • Publication number: 20120149679
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.
    Type: Application
    Filed: February 20, 2012
    Publication date: June 14, 2012
    Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
  • Patent number: 8158661
    Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 17, 2012
    Assignee: Noscira, S.A.
    Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo Del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
  • Patent number: 7977332
    Abstract: Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U, V, X, WR6 and R7 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 12, 2011
    Assignee: FMC Corporation
    Inventors: David M. Roush, John F. Chiarello, Jianming Yu, Benjamin J. Dugan, George Theodoridis, Manorama M. Patel, Walter H. Yeager, Steven W. Szczepanski
  • Publication number: 20110160211
    Abstract: A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).
    Type: Application
    Filed: April 27, 2009
    Publication date: June 30, 2011
    Inventors: Yasumichi Fukuda, Yoshikazu Asahina, Masanori Takadoi, Masanori Yamamoto
  • Publication number: 20100331283
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Shelley Allen, Ellen Laird, Joseph P. Lyssikatos, John E. Robisnson, Christopher P. Corrette, Robert Kirk DeLisle, Walter C. Voegtti
  • Publication number: 20100197655
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.
    Type: Application
    Filed: January 12, 2010
    Publication date: August 5, 2010
    Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
  • Publication number: 20100063109
    Abstract: The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject.
    Type: Application
    Filed: July 18, 2007
    Publication date: March 11, 2010
    Applicant: University of Rochester
    Inventors: Craig Jordan, Monica Guzman
  • Publication number: 20100029685
    Abstract: This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    Type: Application
    Filed: October 24, 2007
    Publication date: February 4, 2010
    Applicant: NeuroSearch A/S
    Inventors: Bjarne H. Dahl, Dan Peters, Gunnar M. Olsen, Daniel B. Timmermann, Susanne Jorgensen
  • Patent number: 7531561
    Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: May 12, 2009
    Assignee: Noscira, S.A.
    Inventors: Miguel Medina Padilla, Mercedes Alonso Cascón, Isabel Dorronsoro Díaz, Ana Martínez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, María José Pérez Puerto
  • Patent number: 7511149
    Abstract: Insecticidal sulfoximines are produced efficiently and in high yield by the oxidation of the corresponding sulfilimine with ruthenium tetraoxide or an alkali metal permanganate.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: March 31, 2009
    Assignee: Dow AgroSciences LLC
    Inventors: Kim E. Arndt, Douglas C. Bland, David E. Podhorez, James R. McConnell
  • Publication number: 20090075986
    Abstract: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
    Type: Application
    Filed: June 9, 2006
    Publication date: March 19, 2009
    Inventors: Daniel L. Flynn, Peter A. Petillo
  • Publication number: 20080261952
    Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    Type: Application
    Filed: August 16, 2005
    Publication date: October 23, 2008
    Inventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Andrew Simon Swain, Phillppe Wong-Kai-In
  • Patent number: 7439242
    Abstract: Modulators of PPAR? activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: October 21, 2008
    Assignee: Amgen Inc.
    Inventors: Jonathan B. Houze, Lawrence R. McGee, Steven Marc Rubenstein
  • Publication number: 20080153886
    Abstract: The invention relates to the use of heterocyclic compounds in the preparation of a medicament for regenerating damaged neuronal tissue. According to a preferred embodiment, formula I compounds are used to produce a medicament for regenerating neuronal tissue in pathologies or conditions that involve neuronal damage or death in the central nervous system or peripheral nervous system.
    Type: Application
    Filed: February 10, 2006
    Publication date: June 26, 2008
    Applicant: NEUROPHARMA, S.A.
    Inventors: Ana Martinez Gil, Rosario De Luna Medina, Ana Perez Castillo, Mercedes Alonso Cascon
  • Publication number: 20080138291
    Abstract: The present invention discloses sulfonamide A-(Q)n—Ar—SChNHR which are CA IX-selective inhibitors, which selectively bind to the enzyme under hypoxic conditions and are able to reverse the tumor acidification mediated by the enzyme. These compounds are useful in anticancer therapies based on tumor-associated CA isozyme inhibition as well as for hypoxic tumor imaging.
    Type: Application
    Filed: June 20, 2006
    Publication date: June 12, 2008
    Applicant: UNION LIFE SCIENCES LTD.
    Inventors: Claudiu T. Supuran, Andrea Scozzafava
  • Patent number: 7371746
    Abstract: The present invention relates to a 1,2,4-thiadiazole compound of the formula (I) represented by the formula (1): wherein R1? represents C3-C7 alkynyl and X represents C4-C7 straight alkylene optionally substituted with one to four of R2?, C4-C7 straight alkenylene optionally substituted with one to four of R2?, ethylene-oxy-ethylene optionally substituted with one to four of R4?, or ethylene-thio-ethylene optionally substituted with one to four of R4?, R2? represents a halogen atom, trifluoromethyl or C1-C4 alkyl, and R4 represents a fluorine atom or C1-C3 alkyl.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: May 13, 2008
    Assignee: Sumitomo Chemical Company Limited
    Inventors: Hideki Ihara, Daisuke Takaoka, Hajime Mizuno
  • Patent number: 7361675
    Abstract: 1,2,4-Thiadiazole compounds represented by the formula (1) have excellent control activities against harmful arthropods: wherein R1 represents C3-C7 alkynyl group optionally substituted one or more halogen atom(s); R2 a represents a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, a C1-C4 haloalkoxy group, a C1-C4 alkylthio group, a cyano group, or a nitro group, and n is an integer of 0 to 5, provided that, when n is an integer of 2 or more, respective R2s may be the same or different; A represents an oxygen atom, a sulfur atom, a single bond, a CR3R4 group, or NR5; R3 and R4 represent each independently a hydrogen atom or a C1-4 alkyl group; and R5 represent a hydrogen and the like.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: April 22, 2008
    Assignee: Sumitomo Chemical Company Limited
    Inventors: Hideki Ihara, Noriyasu Sakamoto
  • Patent number: 7342031
    Abstract: The thiadiazole compound represented by the formula (A): wherein R1 represents a C1-C7 alkyl group, a C3-C7 alkenyl group, a C3-C7 alkynyl group and the like; R2 represents a C1-C4 alkyl group substituted with a hetero ring group in which the hetero ring group may be substituted, which the hetero ring group is a five-membered ring containing only an oxygen atom(s) or a sulfur atom(s) as a hetero atom(s); has an excellent arthropod pests controlling activity.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: March 11, 2008
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Hideki Ihara
  • Patent number: 7273879
    Abstract: A thiadiazole compound of the formula (A): wherein R1 represents methyl, C3-C7 alkenyl, C2-C7 alkoxyalkyl, C2-C7 alkylthioalkyl, C4-C7 alkoxyalkoxyalkyl, C4-C7 alkylthioalkoxyalkyl, phenyl C1-C2 alkyl in which phenyl may be substituted, phenyloxy C1-C2 alkyl in which phenyloxy may be substituted, phenyl C2-C3 alkoxyalkyl in which phenyl may be substituted, or the substituent of the formula (B): wherein R3 represents C1-C3 alkyl, and R4 represents a hydrogen atom, methyl, ethyl or phenyl which may be substituted; and R2 represents phenyl C1-C4 alkyl in which phenyl may be substituted, pyridyl C1-C4 alkyl in which pyridyl may be substituted, or pyrimidyl C1-C4 alkyl in which pyrimidyl may be substituted; has an excellent arthropod pests controlling activity.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: September 25, 2007
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Hideki Ihara, Noriyasu Sakamoto, Hiroki Tomioka
  • Patent number: 7141672
    Abstract: This invention provides compounds of Formula I having the structure or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: November 28, 2006
    Assignee: Wyeth
    Inventor: Michael S. Malamas
  • Patent number: 7015329
    Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: March 21, 2006
    Assignee: Janssen Pharmaceutica N. V.
    Inventors: Gee-Hong Kuo, Lan Shen, Aihua Wang, Yan Zhang
  • Patent number: 6861106
    Abstract: Dichroic dyes, dichroic dye compositions, and liquid crystal composition and liquid crystal display element containing the dichroic dyes. The dichroic dye has increased solubility and stability.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: March 1, 2005
    Assignee: Industrial Technology Research Institute
    Inventors: Shih-Hsien Liu, Yang-Chu Lin, Woan-Shiow Tzeng, Jie-Hwa Ma, Kung-Lung Cheng, Long-Li Lai
  • Publication number: 20040135117
    Abstract: Dichroic dyes, dichroic dye compositions, and liquid crystal composition and liquid crystal display element containing the dichroic dyes. The dichroic dye has increased solubility and stability.
    Type: Application
    Filed: May 23, 2003
    Publication date: July 15, 2004
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Shih-Hsien Liu, Yang-Chu Lin, Woan-Shiow Tzeng, Jie-Hwa Ma, Kung-Lung Cheng, Long-Li Lai
  • Publication number: 20040106795
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Application
    Filed: September 29, 2003
    Publication date: June 3, 2004
    Inventors: Ajita Bhat, Siegfried B. Christensen IV, James S. Frazee, Martha S. Head, Jack D. Leber, Mei Li
  • Patent number: 6699896
    Abstract: This invention provides compounds having the structure wherein A is OR5, or R1 is alkyl, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl, R2 is H, alkyl, or aryl; R3 and R4 are halo, H, alkyl, aryl, trifluoromethyl, alkoxyaryl, nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfonamide, —NR7(CH2)mCO2H, arylsulfonamide, cycloalkyl, or a heterocycle; R5 is H, alkyl, —CH(R8)R9, —CH2(CH2)nCO2R10, —C(CH3)2CO2R10, —CH(R8)(CH2)nCO2R10, —CH(R8)C6H4CO2R10, or —CH2-tetrazole; R6 is H, alkyl, halo, alkoxy, trifluoroalkyl or trifluoroalkoxy; R7 is H or alkyl; R8 is H, alkyl, aryl, arylalkyl, cycloalkyl, phthalic acid, R9 is CO2R12, CONHR12, tetrazole, or PO3R12; R10 is H, alkyl, aryl, or aralkyl; R11 is alkyl; R12 is H, alkyl, aryl, or aralkyl; X is O, or S; Y is O, N, or S; Z is C, or N; Q is O, N, or S; m=1-3; n=1-6, or a pharmaceutically acceptable salt thereof, which
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 2, 2004
    Assignee: Wyeth
    Inventor: Michael S. Malamas
  • Publication number: 20030045557
    Abstract: The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: 1
    Type: Application
    Filed: October 1, 2001
    Publication date: March 6, 2003
    Inventors: Fabrice Vergne, Pierre Ducrot, Charles Andrianjara, Patrick Bernardelli, Edwige Lorthois
  • Patent number: 6500944
    Abstract: The invention relates to the chemical synthesis of oligonucleotides and to chemical entities useful in such synthesis. More particularly, the invention relates to sulfurization of the internucleotide linkages of oligonucleotides. The invention provides a process to synthesize new sulfur transfer reagents and a process for their use in sulfurizing oligonucleotides. The sulfur transfer reagents according to the invention are inexpensive to make, stable in storage and in solution, and highly efficient in sulfurization.
    Type: Grant
    Filed: July 16, 1997
    Date of Patent: December 31, 2002
    Assignee: Avecia Biotechnology, Inc.
    Inventors: Saroj K. Roy, Jin-Yan Tang
  • Patent number: 6492421
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: December 10, 2002
    Assignees: Athena Neurosciences, Inc., American Home Products Corp.
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Louis John Lombardo, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Michael S. Dappen, Reinhardt Bernhard Baudy, Susan Ashwell
  • Patent number: 6468977
    Abstract: Novel 1,2,4-thiadiazole compounds are provided, which are effective as inhibitors of cysteine activity-dependent enzymes and in particular of cysteine proteases. The compounds are useful in treating acne by inhibition of transglutaminase, common cold by inhibition of human rhinovirus 3C protease and inflammatory joint disease by inhibition of cathepsins. The compounds of the present invention are 3,5-disubstituted 1,2,4-thiadazole of the general formula (I): where Z is a nitrogen containing group with recognition sequence for the enzyme and Y is a substituent that tunes the reactivity of the inhibitor towards the thiol group of the cysteine activity-dependent enzyme. The Y group may also serve in recognition.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: October 22, 2002
    Assignee: Apotex Inc.
    Inventors: Khashayar Karimian, Tim Fat Tam, Regis C. S. H. Leung-Toung, Wanren Li, Steve Patrick Bryson, Jolanta Maria Wodzinska
  • Publication number: 20020102489
    Abstract: There is disclosed a novel color-developing agent of a 1,2,4-thiadiazol-5-yl hydrazine type. There is also disclosed a silver halide photographic light-sensitive material which gives sufficient color formation by development and forms an image excellent in image quality and image storability, by using the color-developing agent. Further, there is disclosed an image-forming method using the light-sensitive material.
    Type: Application
    Filed: June 25, 2001
    Publication date: August 1, 2002
    Inventors: Osamu Uchida, Yasuhiro Ishiwata, Kiyoshi Takeuchi, Taiji Katsumata, Takashi Nakamura
  • Patent number: 6380386
    Abstract: The invention relates to novel substituted aminosalicylamides, to a plurality of processes for their preparation and to their use as fungicides, and also to novel intermediates and to a plurality of processes for their preparation.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: April 30, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Seitz, Uwe Stelzer, Peter Wolfrum, Klaus Stenzel
  • Publication number: 20020010326
    Abstract: In our research, 3-phenyl-1,2,4-dithiazoline-5-one is found to be a potential sulfur-transfer reagent. The efficiency and optimization of this new sulfur-transfer reagent was investigated by solid-phase syntheses of dinucleotide phosphorothioate and 25 mer oligonucleotide phosphorothioates at 1 &mgr;mol and 200 &mgr;mol scales. The results show that 3-phenyl-1,2,4-dithiazoline-5-one is a highly efficient sulfurizing reagent, and greater than 99.8% sulfur transfer efficiency can be achieved. In contrast to EDITH or Beaucage reagent, this novel sulfur-transfer reagent is highly stable in storage and in solution, highly soluble in CH3CN solvent, and can be synthesized at a low cost because of the single step reaction. Due to these advantages, 3-phenyl-1,2,4-dithiazoline-5-one can be considered as a better alternative to EDITH or Beaucage reagent, especially in large-scale preparation of oligonucleotide phosphorothioates.
    Type: Application
    Filed: July 16, 1997
    Publication date: January 24, 2002
    Inventors: SAROJ K. ROY, JIN YAN TANG
  • Patent number: 6323315
    Abstract: The present invention provides compounds of the formula where R1-R5 are each, independently, a hydrogen atom or a normal or branched C1-C6-alkyl group; A is a methionyl, phenylalanyl or phenylglycyl residue; n is 0 or 1; R6 is a hydrogen atom; and R7 is a carbocylic group, an aromatic group, a C1-C4-alkyl group, a pyridylalkyl group or a heterocyclic group. In another embodiment, R6 is benzyl or —C(O)OR8, where R8 is a C1-C6-alkyl group, and R7 is a heteroaromatic group, such as a 2-thiazolyl group.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: November 27, 2001
    Assignees: BASF Aktiengesellschaft, Arizona Board of Regents
    Inventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams, Kieran P. M. Durkin, Teresa Barlozzari, Andreas Kling, Bernd Janssen, Andreas Haupt
  • Patent number: 6277994
    Abstract: There is disclosed a novel color-developing agent of a 1,2,4-thiadiazol-5-yl hydrazine type. There is also disclosed a silver halide photographic light-sensitive material which gives sufficient color formation by development and forms an image excellent in image quality and image storability, by using the color-developing agent. Further, there is disclosed an image-forming method using the light-sensitive material.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: August 21, 2001
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Osamu Uchida, Yasuhiro Ishiwata, Kiyoshi Takeuchi, Taiji Katsumata, Takashi Nakamura
  • Patent number: 6262103
    Abstract: A pharamceutical composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein A is C1-6alkyl, C2-6alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, arylC1-6alkyl, aryl, S(O)pR1.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: July 17, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Howard Barff Broughton, Mark Stewart Chambers, Sarah Christine Hobbs, Angus Murray MacLeod, Austin John Reeve
  • Patent number: 6162791
    Abstract: Novel 1,2,4-thiadiazole compounds are provided, which are effective as inhibitors of cysteine activity-dependent enzymes and in particular of cysteine proteases. The compounds are useful in treating acne by inhibition of transglutaminase, common cold by inhibition of human rhinovirus 3C protease and inflammatory joint disease by inhibition of cathepsins. The compounds of the present invention are 3,5-disubstituted 1,2,4-thiadazole of the general formula (I): ##STR1## where Z is a nitrogen containing group with recognition sequence for the enzyme and Y is a substituent that tunes the reactivity of the inhibitor towards the thiol group of the cysteine activity-dependent enzyme. The Y group may also serve in recognition.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: December 19, 2000
    Assignee: Apotex Inc.
    Inventors: Khashayar Karimian, Tim Fat Tam, Regis C. S. H. Leung-Toung, Wanren Li
  • Patent number: 6150374
    Abstract: The invention relates to novel substituted cycloalkenes of the formula (I), ##STR1## to a plurality of processes for their preparation, and to novel intermediates and a plurality of processes for their preparation.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: November 21, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Herbert Gayer, Peter Gerdes, Ralf Tiemann, Stefan Dutzmann, Klaus Stenzel
  • Patent number: 6114537
    Abstract: Thiols are trapped, and converted to disulfide compounds, by a process of reacting them with compounds containing a 1,2,4-thiadiazole ring structure carrying a substituent at position 3 of the thiadiazole ring, and being unsubstituted at position N-2. The process is useful pharmacologically, in inhibiting certain thiol-containing enzymes such as H.sup.+ /K.sup.+ -ATPase (the proton pump), and industrially, in selective removal of thiol compounds from gas or liquid mixtures.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: September 5, 2000
    Assignee: Apotex Inc.
    Inventors: Khashayar Karimian, Tim F. Tam, Denis Desilets, Sue Lee, Tullio Cappelletto, Wanren Li
  • Patent number: 5981556
    Abstract: 1,3-diazolino and 1,3-diazolidino heterocycle derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: November 9, 1999
    Assignee: G.D. Searle & Co.
    Inventors: Donald W. Hansen, Jr., Arija A. Bergmanis, Timothy J. Hagen, E. Ann Hallinan, Steven W. Kramer, Suzanne Metz, Karen B. Peterson, Barnett S. Pitzele, Foe S. Tjoeng, Mihaly V. Toth, Mahima Trivedi, R. Keith Webber, Sofya Tsymbalov, Rolando E. Gapud
  • Patent number: 5977149
    Abstract: Cyclic amides of Formula (I) which are useful as fungicides wherein: A is O; S; N; NR.sup.5 ;or CR.sup.14--, G is C or N; W is O or S; X is OR.sup.1, S(O).sub.m R.sup.1 or halogen; R.sup.1, R.sup.2, and R.sup.5 are independently, in part, C.sub.1 -C.sub.6 alkyl; Y is, in part, --O--; --S(O).sub.n --,--CHR.sup.6 O--; or --CHR.sup.6 O--N.dbd.C(R.sup.7)--; Z is, in part, optionally substituted cycloalkyl, phenyl, pyridinyl, pyrimidinyl, or naphthyl; and R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.14, m, and n are defined in the disclosure, are disclosed.
    Type: Grant
    Filed: January 14, 1998
    Date of Patent: November 2, 1999
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Richard James Brown, King-Mo Sun, Deborah Ann Frasier
  • Patent number: 5972978
    Abstract: The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of formula (I)(L).sub.n --Ar.sub.1 --R.sub.1 A (I)wherein(L).sub.n, n, Ar.sub.1, R.sub.1 and A are as defined in the application.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: October 26, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Sune Andersen, Niels Peter Hundahl Moller, Peter Madsen
  • Patent number: 5958957
    Abstract: The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of formula (I)(L).sub.n --Ar.sub.1 --R.sub.1 --A (I)wherein(L).sub.n, n, Ar.sub.1, R.sub.1 and A are as defined in the application.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: September 28, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Sune Andersen, Niels Peter Hundahl Moller, Peter Madsen